All Stories

  1. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression
  2. Large Individual Differences in Functional Connectivity in the Context of Major Depression and Antidepressant Pharmacotherapy
  3. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes ...
  4. Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 report
  5. Large Individual Differences in Functional Connectivity in the Context of Major Depression and Antidepressant Pharmacotherapy
  6. Values and preferences related to workplace mental health programs and interventions: An international survey
  7. Values and Preferences Related to Workplace Mental Health Programs and Interventions: An International Survey
  8. Co-design of virtual reality cognitive remediation program (bWell-D) with patient end-users and clinicians: A qualitative study (Preprint)
  9. Co-design of a virtual reality cognitive remediation program for depression (bWell-D) with patient end-users and clinicians: A qualitative study (Preprint)
  10. Blue-Light Therapy for Seasonal and Non-Seasonal Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  11. Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 Report
  12. The Effectiveness of Internet-guided Self-help Interventions to Promote Physical Activity Among Individuals with Depression: Systematic Review (Preprint)
  13. The effectiveness of internet-guided self-help interventions to promote physical activity among individuals with depression: A systematic review (Preprint)
  14. Advancing Implementation Science Measurement for Global Mental Health Research
  15. Subcutaneous and Intramuscular Parental Ketamine for Treatment of Depression: Clinical Treatment Protocol
  16. “One Degree of Separation”: A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19
  17. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A CAN-BIND Study
  18. Biophysical compartment models for single-shell diffusion MRI in the human brain: a model fitting comparison
  19. Patient Attitudes About Light Therapy and Negative Ion Therapy for Nonseasonal Depression: An Online Survey Study
  20. Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report
  21. EMBED Phase 2 Study Protocol v.1.4: A Cluster Randomized Controlled Trial of Enhanced versus Standard Measurement-Based Care Implementation for Depression
  22. Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response
  23. Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine
  24. Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report
  25. Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1
  26. Weight gain as a risk factor for progressive neurochemical abnormalities in first episode mania patients: a longitudinal magnetic resonance spectroscopy study
  27. Probing the clinical and brain structural boundaries of bipolar and major depressive disorder
  28. Exploring the Effects of Temperament on Gray Matter Volume of Frontal Cortex in Patients with Mood Disorders
  29. Implementing Measurement-Based Care for Depression: Practical Solutions for Psychiatrists and Primary Care Physicians
  30. Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Prof...
  31. Mental Health Service Challenges during the Early Stage of the COVID-19 Pandemic: Experience and Best Practices from China
  32. The APEC Digital Hub-WONCA Collaborative Framework on Integration of Mental Health into Primary Care in the Asia Pacific
  33. Association of Serum Vitamin D Levels with Depression in Adults: A Nationwide Population-based Study in Korea
  34. The Quality of Life in Bipolar Disorder (QoL.BD) Questionnaire a decade on – A systematic review of the measurement of condition-specific aspects of quality of life in bipolar-disorder
  35. Our Digital Moment: Innovations and Opportunities in Digital Mental Health Care
  36. Quality of Life Impacts of Bright Light Treatment, Fluoxetine, and the Combination in Patients with Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial
  37. A Randomized Sham-controlled Trial of 1-Hz and 10-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) of the Right Dorsolateral Prefrontal Cortex in Civilian Post-traumatic Stress Disorder
  38. Cannabidiol as a Treatment for Mood Disorders: A Systematic Review
  39. Light Therapy for Patients With Bipolar Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials
  40. Men’s Work-Related Stress and Mental Health: Illustrating the Workings of Masculine Role Norms
  41. Risperidone Adjunctive Therapy Duration in the Maintenance Treatment of Bipolar I Disorder: A Post hoc Analysis
  42. Discrepancy between objective and subjective cognition in major depressive disorder
  43. Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective MRI study
  44. Revising Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project
  45. Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder
  46. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report
  47. Evidence for the Efficacy of Bright Light Therapy for Bipolar Depression
  48. Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers
  49. Use of Placebo in Clinical Trials of Psychotropic Medication
  50. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial
  51. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
  52. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study
  53. Implications of Cannabis Legalization on Youth and Young Adults
  54. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials
  55. Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management
  56. Impact of Cognitive Impairment on Functioning in Patients With Depression
  57. A multicomponent intervention for the management of chronic pain in older adults: study protocol for a randomized controlled trial
  58. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial
  59. Subcortical structural volumes in recently remitted first episode mania
  60. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine
  61. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder
  62. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement
  63. A sparse representation-based method for parcellation of the resting brain and its application to treatment-resistant major depressive disorder
  64. Quality of life in bipolar disorder: towards a dynamic understanding
  65. The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction
  66. Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression
  67. The Efficacy of Psychostimulants in Major Depressive Episodes
  68. A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR
  69. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis
  70. Adjunctive ketamine in electroconvulsive therapy: Updated systematic review and meta-analysis
  71. MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes
  72. Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression
  73. A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder
  74. Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder
  75. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study
  76. APEC digital hub for mental health
  77. Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines
  78. Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
  79. Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study
  80. Structural brain changes in first episode mania with and without psychosis: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
  81. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials
  82. The Effects of an E-Mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers: Protocol for a Randomized Controlled Trial
  83. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
  84. S-adenosyl methionine (SAMe) for depression in adults
  85. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder
  86. Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome
  87. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  88. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  89. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  90. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  91. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  92. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  93. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  94. Heparin-Based Polyelectrolyte Complex Enhances the Therapeutic Efficacy of Bone Morphogenetic Protein-2 for Posterolateral Fusion in a Large Animal Model
  95. Preferred Features of E-Mental Health Programs for Prevention of Major Depression in Male Workers: Results From a Canadian National Survey
  96. Selection of cognitive tests for trials of therapeutic agents
  97. Ketamine: stimulating antidepressant treatment?
  98. Midodrine for severe orthostatic hypotension
  99. The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  100. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
  101. Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder
  102. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder
  103. Sinus Tachycardia Induced by Methocarbamol and Repetitive Transcranial Magnetic Stimulation (rTMS)
  104. Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder
  105. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial
  106. Enhanced inflammatory and T-helper-1 type responses but suppressed lymphocyte proliferation in patients with seasonal affective disorder and treated by light therapy
  107. Corrigendum to “A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: Efficacy and tolerability” [J Psychiatr Res (2015) 62: 23–30]
  108. Course and outcome following a first episode of mania: Four-year prospective data from the Systematic Treatment Optimization Program (STOP-EM)
  109. Recovery and Recurrence Following a First Episode of Mania
  110. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: Efficacy and tolerability
  111. Verbal memory impairment in new onset bipolar disorder: Relationship with frontal and medial temporal morphology
  112. The relationship between burnout and depressive symptoms in patients with depressive disorders
  113. STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!
  114. The Relationship Between Neurocognitive and Psychosocial Functioning in Major Depressive Disorder
  115. Neurocognitive Functioning in Overweight and Obese Patients with Bipolar Disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
  116. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine
  117. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder
  118. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
  119. Body Mass Index–Related Regional Gray and White Matter Volume Reductions in First-Episode Mania Patients
  120. Cognitive Change in the Year After a First Manic Episode
  121. Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions
  122. Research-Track Programs for Residents in Psychiatry: A Review of Literature and a Report of 3 Canadian Experiences
  123. Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder
  124. Long-Term Neuropsychological Safety of Subgenual Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
  125. Childhood maltreatment and corpus callosum volume in recently diagnosed patients with bipolar I disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
  126. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
  127. Preclinical evaluation of strontium-containing bioactive bone cement
  128. 12-month longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder
  129. Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder
  130. Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder
  131. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials
  132. Do the symptoms of bipolar disorderreallyshow seasonal variation?
  133. Relationship between frontostriatal morphology and executive function deficits in bipolar I disorder following a first manic episode: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
  134. The impact of childhood trauma on cognitive functioning in patients recently recovered from a first manic episode: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
  135. Author response
  136. Escitalopram and QTc prolongation
  137. Fatigue and occupational functioning in major depressive disorder
  138. Conceptualising the neurobiology of fatigue
  139. A double-blind, placebo-controlled study of adjunctive calcitonin nasal spray in acute refractory mania
  140. Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines
  141. Antidepressants and QTc prolongation
  142. The relationship between clinical outcomes and quality of life in first-episode mania: a longitudinal analysis
  143. Systematic review of neurocognition and occupational functioning in major depressive disorder
  144. The Prevalence and Impact of Depression in Self-Referred Clients Attending an Employee Assistance Program
  145. The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
  146. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis
  147. Selective-serotonin reuptake inhibitors
  148. Positron Emission Tomography Study of the Effects of Tryptophan Depletion on Brain Serotonin 2 Receptors in Subjects Recently Remitted From Major Depression
  149. Seasonal Affective Disorders
  150. Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder
  151. Letter to the Editor
  152. A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression
  153. Which Depressive Symptoms and Medication Side Effects Are Perceived by Patients as Interfering Most with Occupational Functioning?
  154. Onset, time course and trajectories of improvement with antidepressants
  155. Direct Health Care Costs of Treating Seasonal Affective Disorder: A Comparison of Light Therapy and Fluoxetine
  156. Do symptoms of bipolar disorder exhibit seasonal variation? A multisite prospective investigation
  157. The Association of Elevated Body Mass Index with Reduced Brain Volumes in First-Episode Mania
  158. Clinical effectiveness: The importance of psychosocial functioning outcomes
  159. Adjunctive Medication Strategies for Treatment- Resistant Depression
  160. Evaluation of a disease-management intervention designed to reduce depression disability
  161. Comparative efficacy of escitalopram in the treatment of major depressive disorder
  162. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
  163. Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder
  164. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial
  165. Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and meta-analysis
  166. Review: The importance of early symptom relief in antidepressant treatment: focus on agomelatine
  167. Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)
  168. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis
  169. Relief of Chronic or Resistant Depression (Re-ChORD): A pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression
  170. Effect of electroconvulsive therapy on brain 5-HT2 receptors in major depression
  171. A Season-of-Birth/DRD4 Interaction Predicts Maximal Body Mass Index in Women with Bulimia Nervosa
  172. Neurocognitive Functioning in Patients With Bipolar I Disorder Recently Recovered From a First Manic Episode
  173. Brain serotonin-2 receptors in acute mania
  174. A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder
  175. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.
  176. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.
  177. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.
  178. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication
  179. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management
  180. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults
  181. Evidence of a Biological Effect of Light Therapy on the Retina of Patients with Seasonal Affective Disorder
  182. Review: high frequency repetitive transcranial magnetic stimulation improves symptoms of treatment resistant major depression
  183. Course and Outcome after the First Manic Episode in Patients with Bipolar Disorder: Prospective 12-Month Data from the Systematic Treatment Optimization Program for Early Mania Project
  184. Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project
  185. Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder
  186. Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder
  187. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder
  188. Addressing circadian rhythm disturbances in depressed patients
  189. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Metaanalysis
  190. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials
  191. Burden of Bipolar Depression
  192. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders
  193. Which antidepressants have demonstrated superior efficacy? A review of the evidence
  194. A magnetic resonance imaging study of mood stabilizer- and neuroleptic-naïve first-episode mania
  195. Seasonal Affective Disorder: A Clinical Update
  196. High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder
  197. A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD)
  198. The impact of bipolar disorder upon work functioning: a qualitative analysis
  199. A pilot study of adherence with light treatment for seasonal affective disorder
  200. Long-Term and Preventative Treatment for Seasonal Affective Disorder
  201. Quality of life as an outcome indicator in patients with seasonal affective disorder: results from the Can-SAD study
  202. A Birth-Season/DRD4 Gene Interaction Predicts Weight Gain and Obesity in Women with Seasonal Affective Disorder: A Seasonal Thrifty Phenotype Hypothesis
  203. The Influence of Baseline Severity on Efficacy of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: An Extended Analysis
  204. Personality and seasonal affective disorder: Results from the CAN-SAD study
  205. Oxcarbazepine in the Treatment of Bipolar Disorder: A Review
  206. A Birth-Season/DRD4 Gene Interaction Predicts Weight Gain and Obesity in Women with Seasonal Affective Disorder: A Seasonal Thrifty Phenotype Hypothesis
  207. The Can-SAD Study: A Randomized Controlled Trial of the Effectiveness of Light Therapy and Fluoxetine in Patients With Winter Seasonal Affective Disorder
  208. Sleep disturbances and depression: a challenge for antidepressants
  209. O sweet spot where art thou? Light treatment of Seasonal Affective Disorder and the circadian time of sleep
  210. Bipolar Disorder and Quality of Life: A Patient-Centered Perspective
  211. The Relevance of an Employee Assistance Program to the Treatment of Workplace Depression
  212. EDITORIAL
  213. Generalized anxiety disorder: how to treat, and for how long?
  214. Challenges in the treatment of anxiety disorders: beyond guidelines
  215. Oxcarbazepine add-on in the treatment of refractory bipolar disorder
  216. A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania
  217. Update on the Biology of Seasonal Affective Disorder
  218. Quality of Life in Patients with Seasonal Affective Disorder: Summer vs Winter Scores
  219. Chronotherapeutics (light and wake therapy) in affective disorders
  220. Using Metaanalysis to Evaluate Evidence: Practical Tips and Traps
  221. Perceived Quality of Life in Patients with Bipolar Disorder. Does Group Psychoeducation Have an Impact?
  222. Therapeutic Mechanism in Seasonal Affective Disorder: Do Fluoxetine and Light Operate Through Advancing Circadian Phase?
  223. Treatment of seasonal affective disorder: Unipolar versus bipolar differences
  224. The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: An evolutionary perspective
  225. Generic and health-related quality of life in patients with seasonal and nonseasonal depression
  226. Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis
  227. Priorities in treating depression only
  228. A Comparison of Personality Function Among Patients with Seasonal Depression, Nonseasonal Depression, and Nonclinical Participants
  229. Electroretinography in patients with winter seasonal affective disorder
  230. Hard Times and Good Friends: Negative Life Events and Social Support in Patients with Seasonal and Nonseasonal Depression
  231. Citalopram and Bupropion-SR
  232. Brightening Depression
  233. Editorial
  234. Does neuroimmune dysfunction mediate seasonal mood changes in winter depression?
  235. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics
  236. Acute tryptophan depletion (ATD) induces depressive symptoms in subgroups of recovered depressed patients, including those with seasonal affective disorder (SAD) (Van der Does, 2001a, review).
  237. Childhood Inattention and Dysphoria and Adult Obesity Associated with the Dopamine D4 receptor Gene in Overeating Women with Seasonal Affective Disorder
  238. The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality
  239. Review: antidepressants and psychotherapy may be equally effective for promoting remission in major depressive disorder
  240. The interpersonal expression of perfection: Perfectionistic self-presentation and psychological distress.
  241. Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future
  242. PET Study of the Effects of Valproate on Dopamine D 2 Receptors in Neuroleptic- and Mood-Stabilizer-Naive Patients With Nonpsychotic Mania
  243. Evidence Supports Validity of Seasonal Affective Disorder
  244. Seasonal Affective Disorder: The Latitude Hypothesis Revisited
  245. Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder
  246. A comparison of open treatment of seasonal major and minor depression with light therapy
  247. Breaking the Myths: New Treatment Approaches for Chronic Depression
  248. Combining Antidepressants for Treatment-Resistant Depression
  249. PET Study of [ 18 F]6-Fluoro- l -Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium
  250. Effects of Alpha-Methyl-Para-Tyrosine-Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission
  251. Effects of rapid tryptophan depletion on brain 5-HT2 receptors: a PET study
  252. An Open Trial of Light Therapy for Women With Seasonal Affective Disorder and Comorbid Bulimia Nervosa
  253. Seasonal depression
  254. Immune–inflammatory markers in patients with seasonal affective disorder: effects of light therapy
  255. Patients' preferences and counselling for depression in primary care
  256. A PET study of brain 5-HT 2 receptors and their correlation with platelet 5-HT 2 receptors in healthy humans
  257. Brain Serotonin2 Receptors in Major Depression
  258. Does the Addition of Pindolol Accelerate the Response to Electroconvulsive Therapy in Patients with Major Depression? A Double-Blind, Placebo-Controlled Pilot Study
  259. Review: lithium augmentation increases treatment response in refractory depression
  260. Erratum to “Growth hormone to baclofen in patients with seasonal affective disorder: effects of light therapy”
  261. Effects of Light Therapy on Suicidal Ideation in Patients With Winter Depression
  262. Effects of rapid tryptophan depletion in patients with seasonal affective disorder in natural summer remission
  263. Growth hormone response to baclofen in patients with mania: a pilot study
  264. Hypothermic, ACTH, and cortisol responses to ipsapirone in patients with mania and healthy controls
  265. Decrease in Brain Serotonin 2 Receptor Binding in Patients With Major Depression Following Desipramine Treatment
  266. Adverse Effects of Pindolol Augmentation in Patients With Bipolar Depression
  267. A controlled study of light therapy in women with late luteal phase dysphoric disorder
  268. Clinical Predictors of Short-Term Outcome in Electroconvulsive Therapy
  269. Growth hormone response to baclofen in patients with seasonal affective disorder: effects of light therapy
  270. A Canadian Multicenter Study of Three Fixed Doses of Controlled-Release Ipsapirone in Outpatients With Moderate to Severe Major Depression
  271. A Community-Based Clinic Survey of Antidepressant Use in Persons with Schizophrenia
  272. Effects of lamotrigine on the 5-HT1A receptor function in healthy human males
  273. Divalproex Sodium Attenuates Growth Hormone Response to Baclofen in Healthy Human Males
  274. Seasonal mood change and personality: an investigation of genetic co-morbidity
  275. Cortisol, Hypothermic, and Behavioral Responses to Ipsapirone in Patients with Bipolar Depression and Normal Controls
  276. Effects of Divalproex Sodium on 5-HT1A Receptor Function in Healthy Human Males: Hypothermic, Hormonal, and Behavioral Responses to Ipsapirone
  277. Mania, Depression, and Mood Dependent Memory
  278. Sumatriptan-Induced Growth Hormone Release in Patients with Major Depression, Mania, and Normal Controls
  279. Seasonality of symptoms in women with late luteal phase dysphoric disorder
  280. Growth hormone response to sumatriptan (5-HT1D agonist) challenge in seasonal affective disorder: Effects of light therapy
  281. Atypical depressive symptoms in seasonal and non-seasonal mood disorders
  282. The relationship between seasonal mood change and personality: more apparent than real?
  283. Gender differences in the heritability of seasonal mood change
  284. L-Tryptophan Augmentation of Light Therapy in Patients with Seasonal Affective Disorder
  285. Effects of chronic lithium treatment on retinal electrophysiologic function
  286. Light Therapy for Depressive Disorders: Indications and Efficacy
  287. Atypical depressive symptoms and clusters in unipolar and bipolar depression
  288. The validity of atypical depression in DSM-IV
  289. Effect of Stimulus Intensity on Prolactin and Cortisol Release Induced by Unilateral Electroconvulsive Therapy
  290. Major depression, minor depression, and double depression: Are they distinct clinical entities?
  291. Role of serotonin3 receptors in prolactin release induced by electroconvulsive therapy: A study with ondansetron
  292. Seasonality of symptoms in anorexia and bulimia nervosa
  293. Effects of Rapid Tryptophan Depletion in Patients With Seasonal Affective Disorder in Remission After Light Therapy
  294. Treatment of Seasonal Affective Disorder: A Review
  295. Prolactin response to buspirone challenge in the presence of dopaminergic blockade
  296. Mood disorder service genetic database: Morbidity risks for mood disorders in 3,942 first-degree relatives of 671 index cases with single depression, recurrent depression, bipolar I, or bipolar II
  297. Research Funding of Psychiatric Disorders in Canada: A Snapshot, 1990–1991
  298. Morning light therapy for winter depression: predictors of response
  299. Eating attitudes in seasonal affective disorder and bulimia nervosa
  300. Obtaining a Family Psychiatric History: Is it Worth the Effort?
  301. Comparison of fluoxetine and desipramine in depressed outpatients
  302. Chronic Schizophrenia and Idiopathic Parkinson's Disease
  303. Light visor treament for seasonal affective disorder: A multicenter study
  304. Electroretinography in seasonal affective disorder
  305. Hypersomnia and morning light therapy for winter depression
  306. The effects of ultraviolet-A wavelengths in light therapy for seasonal depression
  307. Seasonal mood symptoms in bulimia nervosa and seasonal affective disorder
  308. Seasonal Affective Disorder Presenting as Chronic Fatigue Syndrome
  309. ECT-induced prolactin release: Effect of sex, electrode placement and serotonin uptake inhibition
  310. Melatonin suppression in bipolar and unipolar mood disorders
  311. A Psychiatric Fellowship in the United States
  312. Treatment of depression in patients with dementia
  313. Light therapy for seasonal bulimia
  314. Phototherapy for Depressive Disorders: A Review
  315. The Clinical Use of EEG in a General Psychiatric Setting
  316. The Lateralization of Atypical Facial Pain
  317. Antidepressant Drug Studies in the Elderly
  318. Quality of life impairment in bipolar disorder